1887
Letter Open Access
Like 0
Preview this article:

There is no abstract available.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.2.2500974
2026-01-15
2026-02-07
/content/10.2807/1560-7917.ES.2026.31.2.2500974
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/2/eurosurv-31-2-7.html?itemId=/content/10.2807/1560-7917.ES.2026.31.2.2500974&mimeType=html&fmt=ahah

References

  1. Moschese D, Esvan R, Fusetti C, Barchi V, Cossu MV, Giacinta A, et al. Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025. Euro Surveill. 2025;30(39):2500739.  https://doi.org/10.2807/1560-7917.ES.2025.30.39.2500739  PMID: 41040064 
  2. Brunoro R, Mengato D, Giunco E, Barbaro F, Cattelan AM, Venturini F. Comparing self-reported and pharmacy-based monitoring adherence rates in individual accessing HIV Pre-Exposure Prophylaxis (PrEP): an 18-month retrospective analysis. Sex Transm Infect. 2025;101(Suppl 1):A69, Abstract OC73.  https://doi.org/10.1136/sextrans-ICAR-2025.65 
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error